2022-08-31 08:00 Regulatory Interim
Significant events during the first quarter · Results with DiviTum®TKa at ASCO · DiviTum®TKa highlighted at ASCO in an oral presentation · Biovica’s CFO will terminate employment in December 2022 ·...
2022-08-15 15:00 Regulatory
Biovica, active in cancer diagnostics, is hosting a market update due DiviTum®TKa’s US market approval received on July 29 from the US Food and Drug Administration (FDA). At the update on Thursday 18 August 15.00-16.00 CET, CEO Anders Rylander...
2022-07-30 13:00 Regulatory
Biovica, active in cancer diagnostics, today announces that FDA has granted 510(k) clearance for the product DiviTum®TKa as an aid in monitoring disease progression in previously diagnosed hormone receptor positive, metastatic postmenopausal female...
2022-07-27 08:00 Regulatory
The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the annual general meeting on Wednesday 31 August 2022. The board of directors has decided that the annual general meeting shall only be...
2022-06-30 17:45 Regulatory
Biovica, active in cancer diagnostics, today announces that the company’s CFO and deputy CEO Cecilia Driving today has submitted her letter of resignation. A process to recruit a replacement is immediately initiated. Cecilia Driving, who has been...
2022-06-30 08:00 Regulatory Annual
Annual report for the financial year 2021/2022 for Biovica International AB is published today on our website. Financials – Biovica Contact Anders Rylander, CEO Phone: +46-18-444 48 35 E-mail: anders.rylander@biovica.com Cecilia Driving, EVP CFO...
2022-06-16 08:00 Regulatory Interim
Significant events during the fourth quarter Significant events after the end of the period Audiocast: When: 16 June 2022 at 15.00 CET Where: https://tv.streamfabriken.com/biovica-international-q4-2021-2022 Phone numbers: SE: +46856642692, DK: +4578723252...
2022-06-13 10:00 Regulatory
Biovica today announced that the company’s blood test DiviTum®TKa was highlighted in an oral presentation on June 6th at the ASCO Annual Meeting from the BioItaLEE trial. The study results suggest that TKa can predict patients’ response...
2022-05-09 13:15 Regulatory
Biovica, active in cancer diagnostics, today announces that the company's blood test DiviTum®TKa will be included in one oral presentation and two abstracts/posters, at the world's largest cancer congress, ASCO Annual Meeting, June 3-7, 2022, in Chicago...
2022-04-28 18:00 Regulatory
Biovica, active in cancer diagnostics, today announces that the company has submitted its updated 510(k)-application to the U.S. Food and Drug Administration (FDA) to receive marketing authorization for the blood-based biomarker assay DiviTum®TKa...

Some of our Collaborations

>3200

Numbers of patients in studies

24

Publications

10

Pharma Contracts